1
/
of
0
FDA Drug Approval, N203629, NEOSTIGMINE METHYLSULFATE
FDA Drug Approval, N203629, NEOSTIGMINE METHYLSULFATE
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
NDA: 203629
Company: FRESENIUS KABI USA
Drug Name: NEOSTIGMINE METHYLSULFATE
Active Ingredients: NEOSTIGMINE METHYLSULFATE
Strength: 3MG/3ML (1MG/ML)
Dosage Form/Route: SOLUTION;INTRAVENOUS
Action Date: 01/08/2015
Marketing Status: Prescription
Submission Classification: Type 3 - New Dosage Form
Company: FRESENIUS KABI USA
Drug Name: NEOSTIGMINE METHYLSULFATE
Active Ingredients: NEOSTIGMINE METHYLSULFATE
Strength: 3MG/3ML (1MG/ML)
Dosage Form/Route: SOLUTION;INTRAVENOUS
Action Date: 01/08/2015
Marketing Status: Prescription
Submission Classification: Type 3 - New Dosage Form
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details